Vascular Inflammation in Cardiovascular Disease: Is Immune System Protective or Bystander?

Author(s): Khalid Muhammad, Mohammed A. Ayoub, Rabah Iratni*

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 18 , 2021

Become EABM
Become Reviewer
Call for Editor


Cardiovascular disease (CVD) is one of the leading causes of death worldwide. Chronic atherosclerosis induced vascular inflammation and perturbation of lipid metabolism is believed to be a major cause of CVD. Interplay of innate and adaptive Immune system has been interwined with various risk factors associated with the initiation and progression of atherosclerosis in CVD. A large body of evidence indicates a correlation between immunity and atherosclerosis. Retention of plasma lipoproteins in arterial subendothelial wall triggers the T helper type 1 (Th1) cells and monocyte-derived macrophages to form atherosclerotic plaques. In the present review, we will discuss the pathogenesis of CVD in relation to atherosclerosis with a particular focus on pro-atherogenic role of immune cells. Recent findings have also suggested anti-atherogenic roles of different B cell subsets. Therapeutic approaches to target atherosclerosis risk factors have reduced the mortality, but a need exists for the novel therapies to treat arterial vascular inflammation. These insights into the immune pathogenesis of atherosclerosis can lead to new targeted therapeutics to abate cardiovascular mortality and morbidity.

Keywords: Cardiovascular disease, atherosclerosis, T cells, B cells, dendritic cells, lipoproteins.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 18 January, 2021
Page: [2141 - 2150]
Pages: 10
DOI: 10.2174/1381612827666210118121952
Price: $65

Article Metrics

PDF: 58